Using a robotic exoskeleton to help children with movement disorders walk better
A Phase I/II Trial Evaluating Long-Term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders
This study is testing if a robotic exoskeleton can help children with movement disorders walk better and improve their overall movement skills.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 44 (estimated) |
| Ages | 3 Years to 17 Years |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT05726591 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the long-term effects of a robotic exoskeleton designed for children with movement disorders such as cerebral palsy, muscular dystrophy, spina bifida, and incomplete spinal cord injury. Participants aged 3 to 17 will undergo a randomized crossover design, where they will receive either the exoskeleton therapy or continue with standard therapy over three 12-week phases. The study will assess improvements in walking ability, muscle activity, and overall gross motor function through various tests and monitoring of exoskeleton use outside the clinical setting. The primary focus is on improving knee joint function during walking.
Who should consider this trial
Good fit: Ideal candidates are children aged 3 to 17 years with a gait disorder involving the knee joint due to conditions like cerebral palsy or muscular dystrophy.
Not a fit: Patients with severe knee joint limitations or those not meeting the inclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly enhance walking ability and overall mobility in children with movement disorders.
How similar studies have performed: Previous studies have shown promise in using robotic exoskeletons for gait training, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Provision of signed and dated separate informed consent and assent forms for screening purposes. Upon inclusion in the protocol, provision of signed and dated informed consent and assent forms to begin participation in the study will be necessary. * Stated willingness to comply with all study procedures and availability for the duration of the study, or alternatively, ability to do so based on parent report and physician observation during history and physical examination. * Age 3 to 17 years old. * Have a gait pathology involving the knee joint, from a diagnosis of cerebral palsy, muscular dystrophy, spina bifida, or incomplete spinal cord injury. * Knee joint range of motion of at least 25 degrees in the sagittal plane (knee extension/flexion) assessed with hip extended in supine position. Hamstring contracture as assessed by straight leg raising test does not limit ability to participate in the study. * Ankle joint range of motion of at least 15 degrees in the sagittal plane (dorsi-plantar flexion) with the foot in neutral alignment. * A measured foot-thigh angle of -15 to 30 degrees in prone position. * Able to walk at least 10 feet without stopping with or without a walking aid. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Any neurological, musculoskeletal or cardiorespiratory injury, health condition, or diagnosis other than cerebral palsy, muscular dystrophy, spina bifida, or incomplete spinal cord injury that would affect the ability to walk as directed with the robotic exoskeleton. * A history of uncontrolled seizure in the past year. * Pregnancy. A urine test will be performed for all participants who are able to become pregnant at the initial screening visit and in the case of a positive test, the participant will be excluded from participation. Further monitoring will rely on self-reporting of interruption in menstruation that would require re-testing for pregnancy at the next visit. * Any acute cardiopulmonary condition which limits exercise to less than 60 minutes per session or less than 5 days per week.
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Thomas C Bulea, Ph.D. — National Institutes of Health Clinical Center (CC)
- Study coordinator: Thomas C Bulea, Ph.D.
- Email: buleatc@mail.nih.gov
- Phone: (301) 451-7533
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.